Centessa Pharmaceuticals PLC (NAS:CNTA)
$ 17.6 0.3 (1.73%) Market Cap: 2.32 Bil Enterprise Value: 1.89 Bil PE Ratio: 0 PB Ratio: 4.61 GF Score: 39/100

Centessa Pharmaceuticals PLC Discuss Topline Data from Proof-of-Concept Study of SerpinPC Trial Call Transcript

Sep 09, 2021 / 12:30PM GMT
Release Date Price: $22.26 (+5.75%)
Jennifer Porcelli
Centessa Pharmaceuticals - Head, IR

Good morning, everyone. We are pleased you can join us today for the announcement of topline data from our Phase 2a trial of SerpinPC in hemophilia A and hemophilia B patients. Please refer to our press release from this morning as well as the corresponding data presentation. Both of which are available on our website.

During this call, we will be making forward-looking statements. These statements include without limitation, discussions of the open label extension study of SerpinPC and its design and conduct, plans for continued development of SerpinPC including our global development plan and registrational path for this candidate, our expectations with respect to the treatment paradigm for hemophilia A and B and our ability to deliver impactful medicines to patients.

Such statements reflect our current views, estimates and projections only as of today and are subject to a number of risks and uncertainties that could cost actual results to differ materially and adversely from those implied by such forward-looking statements. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot